MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q3 2025 10-Q Quarterly Report
MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
MADRIGAL PHARMACEUTICALS, INC. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $287.3M Q3 2025 vs $62.2M Q3 2024, up 362% due to increased Rezdiffra demand
- • Operating loss stable: $(114.0)M Q3 2025 vs $(116.3)M Q3 2024, 2% improvement
MADRIGAL PHARMACEUTICALS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$287M
▲ +362.0% YoY▲ +35.0% QoQ
Net Income
-$114M
▼ -6.8% YoY▼ -170.1% QoQ
Operating Margin
-39.7%
▲ +14738bp YoY▼ -1749bp QoQ
Net Margin
-39.8%
▲ +13229bp YoY▼ -1988bp QoQ
ROE
-18.2%
Total Assets
$1.4B
EPS (Diluted)
$-5.10
▼ -5.4% YoY▼ -168.4% QoQ
Operating Cash Flow
$80M
▲ +219.2% YoY▲ +269.7% QoQ
Source: XBRL data from MADRIGAL PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on MADRIGAL PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.